2. GPCR/G Protein Neuronal Signaling
  3. Dopamine Receptor
  4. TAT-D1 peptide

TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

TAT-D1 peptide

TAT-D1 peptide Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of TAT-D1 peptide:

Other Forms of TAT-D1 peptide:

TAT-D1 peptide Related Antibodies

Top Publications Citing Use of Products

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms
Dopamine Receptor D1 Receptor D2 Receptor D3 Receptor D4 Receptor D5 Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders[1][2][3].

In Vivo

TAT-D1 peptide (i.c.v.; 15 minutes prior to injection; administered daily for 5 consecutive days; single dose, 300 pM) disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization[1].
TAT-D1 peptide (i.c.v.; single dose, 300 pM) exerts antidepressant-like effects in unstressed rats by reducing the total immobility time in the forced swim test; it exerts anxiolytic-like effects by increasing the time rats spend in the open arms of the elevated plus maze and shortening the feeding latency in the novelty-suppressed feeding test. It exerts rapid antidepressant effects by reversing the anhedonic reduction in sucrose preference in rats exposed to chronic unpredictable stress (CUS), completely reversing the CUS-induced prolongation of feeding latency in a novel environment, and increasing the intake of Froot Loops. It inhibits SKF 83959 (HY-130344)-induced c-fos expression in the nucleus accumbens and SKF 83959-induced grooming behavior, while administration alone induces region-specific c-fos expression in the cortex, anterior olfactory area, lateral habenula and thalamus[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (adult male, 300-350 g)[1]
Dosage: 300 pM (acute pre-administration; co-administration; repeated administration)
Administration: intracerebroventricular (i.c.v.); 15 minutes prior to injection; daily for 5 consecutive days; single dose
Result: Elevated total 60-minute locomotor activity to 2918.1 beam breaks, a significant increase compared to saline controls.
Induced a robust locomotor increase in the first 5 minutes post-injection that was significantly higher than controls.
Did not produce a significant change in locomotor activity in non-habituated rats compared to vehicle controls.
Significantly enhanced locomotor responsiveness to amphetamine across the 5-day regimen compared to amphetamine alone (p < 0.05).
Induced a sensitized locomotor response to the priming amphetamine injection with total 60-minute activity of 7337.0 ± 920.4 beam breaks, significantly higher than saline-pretreated controls and comparable to amphetamine-sensitized rats.
Further enhanced the sensitized locomotor response to the priming amphetamine injection with total 60-minute activity of 8989.3 beam breaks, significantly higher than both saline-pretreated controls and amphetamine-sensitized rats .
Did not alter the expression of locomotor sensitization in amphetamine-sensitized rats, with total 60-minute activity of 7948.5 beam breaks, significantly higher than saline-pretreated controls.
Animal Model: Sprague-Dawley (adult male, 300-400 g); Fischer 344 (adult male, 300-400 g, chronic unpredictable stress model)[2]
Dosage: 300 pM
Administration: i.c.v.; single dose
Result: Significantly reduced total immobility timein forced swim test.
Significantly increased time spent in open arms per entryand reduced total open arm entriesin elevated plus maze.
Significantly reduced latency to drink milk in novel environment in novelty-induced hypophagia test.
Abolished SKF 83959-induced reduction in latency to immobility and increase in immobility within first minute of forced swim test.
Abolished SKF 83959-induced reduction in time spent in open arms per entry and total time spent in open arms in elevated plus maze.
Robustly attenuated SKF 83959-induced enhanced latency to drink milk and reinstated total milk consumption in novelty-induced hypophagia test.
Partially reversed CUS-induced reduction in sucrose preference scores, eliminating significant difference between CUS-exposed and non-exposed control rats.
Completely reversed CUS-induced increase in latency to consume fruit loops to non-stressed control levels; significantly increased total fruit loops consumed in CUS-exposed and non-exposed control rats.
Completely abolished CUS-induced prolongation of feeding latency in novel environment, restoring latency to non-stressed control levels.
Showed no significant effect on total time spent in open arms in elevated plus maze.
Significantly reduced SKF 83959-induced c-fos expression in nucleus accumbens (NAc) core and NAc shell.
Abolished SKF 83959-induced grooming behavior, reducing grooming time.
Induced significant c-fos expression in multiple brain regions when administered standalone: anterior olfactory nucleus, orbitofrontal cortex, infralimbic cortex, prelimbic cortex, piriform cortex, lateral habenula, thalamic nuclei.
Showed no effect on c-fos expression in striatal subregions, ventral pallidum, globus pallidus, lateral hypothalamus, hippocampus, amygdala, substantia nigra, ventral tegmental area, or rostromedial tegmental nucleus when administered standalone.
Molecular Weight

3474.94

Formula

C144H257N57O43
Sequence

Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln-Gly-Ser-Ser-Glu-Asp-Leu-Lys-Lys-Glu-Glu-Ala-Ala-Gly-Ile-Ala-Arg-Pro-Leu
Sequence Shortening

GRKKRRQRRRPQGSSEDLKKEEAAGIARPL
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TAT-D1 peptide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TAT-D1 peptideDopamine Receptordopamine D1-D2 receptor heterodimer inhibitorpsychostimulant addictiondepressionanxiety disordersSprague-Dawley RatFischer ratInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TAT-D1 peptide
Cat. No.:
HY-P10405
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.